Pharming: 3 Key Takeaways for Long-Term Investors

Pharming reported Q3 2026 revenue growth of 21% to $117.6 million with operating profit surging 89% to $29.9 million. The company's core rare disease product RUCONEST stabilized demand, while Joenja accelerated 58% growth through geographic and pediatric expansion. Management is advancing its clinical pipeline into larger immunodeficiency markets with $191 million in cash and no need for external financing.